The prothrombin gene variant G20210A but not factor V Leiden may be associated with veno-occlusive disease following BMT Veno-occlusive disease (VOD) is a major early complication of bone marrow transplantation (BMT). A decrease in the natural anticoagulants, particularly protein C and, to a lesser extent, anti-thrombin III and protein S, have been observed in patients who develop VOD and it is felt that this acquired hypercoagulable state may be involved in the pathogenesis of the disease. 1 Since the majority of genetic defects associated with venous thromboembolic disease affect the protein C anticoagulant pathway, we decided to screen for the presence of the two recently described thrombophilic determinants, factor V Leiden 2 and the prothrombin G20210A 3 in patients who developed VOD. Between May 1984 and December 1996 a total of 209 allogeneic bone marrow transplants (BMT) were performed in St James's Hospital. The donors were as follows: 189 HLA-identical sibling donors, four HLA mismatched family donors, four syngeneic and 12 phenotypically matched unrelated donors. In addition, 78 autografts were performed (total group, n = 287). The median range at transplant was 29 years (range 4-55) with a male:female ratio of 160:127. Conditioning therapy was with cyclophosphamide 120 mg/kg and single fraction TBI n = 142 (10 Gy at 4 cGy/min n = 34 and 7.5 Gy at 18 cGy/min n = 108), busulphan 16 mg/kg and cyclophosphamide 120 mg/kg n = 86, BCNU 300 mg/m 2 , etoposide 1 g/m 2 , cytosine-arabinoside 1g/m 2 and melphalan 140 mg/m 2 (BEAM) n = 30, cyclophosphamide alone 200 mg/kg n = 17, busulphan alone 16 mg/kg n = 5 and thiotepa 800 mg/m 2 with cyclophosphamide 6 g/m 2 n = 7. Graft-versus-host disease prophylaxis in the allogeneic setting was with cyclosporin alone n = 35, ex vivo T cell depletion n = 17, cyclosporin and methotrexate n = 153 and none n = 4.
Fifty-one of the 287 patients who received allogeneic or autologous BMT and on whom pre-transplant material was available for retrospective analysis were used as a control group. A diagnosis of VOD was based on clinical or histological criteria. Clinical diagnosis required all three of the following by day +20: (1) hyperbilirubinaemia Ͼ34.2 mol/l, (2) hepatomegaly and (3) ascites and/or unexplained weight gain. Histological diagnosis of VOD was based on liver specimens obtained by biopsy or at postmortem examination. Pre-transplant material was available for analysis of the two thrombophilic mutations in the control group of 51 patients and in 15/22 patients who subsequently developed VOD. Molecular analysis to detect FV Arg 506-Gln and ProG20210A polymorphisms was performed on stored genomic DNA which had previously been isolated from whole blood, or DNA was extracted from dried blood on haematological slides. For factor V R506Q (1691 G → A) Leiden, genotyping was performed as previously described. 4 For Prothrombin (20210 G → A), a modification of the method by Poort et al 3 was used. There were 22 cases (7.7%) of VOD: 11 patients had histological evidence of VOD (three biopsy, eight autopsy specimens) and 11 fulfilled all three clinical criteria but were not studied histologically. Median time to onset was 10 days (range 7-49). Ten of the 22 patients died with VOD as a primary or contributing cause of death (case fatality rate 45%).
PCR analysis indicated that 0/15 VOD patients tested had the factor V Leiden mutation whereas three of the 51 (5.9%) in the control group patients were heterozygous for this mutation (P = 0.05).
By contrast, two of the 15 (13%) patients with VOD were heterozygous for the prothrombin gene variant compared with none in the control group (P = 0.05).
Veno-occlusive disease of the liver is associated with significant morbidity and mortality. The key event in the development of VOD is damage to the vascular endothelium in the liver which in turn produces a hypercoagulable state, leading to excess thrombin generation. Several surveillance systems operate to counter the harmful effects of thrombin and these include anti-thrombin, heparin co-factor II, tissue factor pathway inhibitor and the fibrinolytic and protein C anticoagulant pathways. It is known that mutations in genes that encode these natural anticoagulant proteins predispose to venous thrombosis. The majority of genetic defects associated with venous thromboembolism affect the protein C pathway and therefore it is reasonable to postulate that inherited defects in any one or more of the members of these pathways (protein C, protein S, thrombomodulin, endothelial protein C receptor, prothrombin/thrombin and factors V and VIII) would be more likely to be present and therefore predispose to VOD, given the fact that coagulation activation is prominent following transplant conditioning. The main reason we chose to screen for the genetic variants FV Leiden and prothrombin G20210A was that, taken together, these account for the vast majority of cases of familial/inherited venous thrombosis. Whilst the true prevalence of these two genetic variants in the Irish population is unknown, preliminary data from our unit suggest that FV Leiden has a similar prevalence to that seen in other Northern European countries, ie approximately 4.4%, which results in a seven-fold increased risk of venous thrombosis in heterozygotes and an 80-fold increase in homozygotes. 2, 5 However, the prothrombin gene variant G20210A, which is associated with elevated plasma prothrombin levels and a 2.8-fold increased risk of venous thrombosis, would appear to have a much lower prevalence in the Irish population (Ͻ0.5%) when compared to other Northern European countries (1-2%). In this study, 6% of the control group were heterozygous for FV Leiden which correlated with the expected prevalence, and interestingly, none of the patients with VOD carried this mutation. Conversely, the prevalence of the prothrombin gene variant in the patients who developed VOD was 13%, much higher than what would be expected, given the prevalence of the normal population to be less than 1%.
We conclude that the prothrombin gene variant probably increases the risk of VOD in BMT patients. Identification of high risk patients may allow early detection of events leading to VOD, and early intervention and treatment of this disease. However, it is interesting that the more common thrombophilic trait, FV Leiden, does not appear to be a predisposing factor for VOD. We recognise that the number of patients in our preliminary study is small and therefore would suggest our findings warrant further studies.
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Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures
Pericentric inversion of chromosome 16 [inv(16)(p13q22)] and the related t(16;16)(p13;q22), 1 resulting in a chimeric fusion of the CBF␤ and MYH11 genes, are seen in a subset of acute myeloid leukemia (AML) patients. [2] [3] [4] The molecular marker is detectable by reverse transcription-polymerase chain reaction assay (RT-PCR) [5] [6] [7] [8] [9] on RNA at the time of diagnosis, and could be particularly useful for monitoring MRD in patients who achieve complete clinical remission (CCR) after induction therapy. [10] [11] [12] [13] Marcucci et al 14 and several other authors 10-13 have reported favorable clinical outcomes despite persistence of CBF␤/MYH11 transcripts detected by RT-PCR; similar findings have been reported for another core-binding-factor altered in AML, 15, 16 in which positive expression of AML1-ETO transcript can persist after induction and consolidation chemotherapy without evidence of hematological relapse. Thus, the definition of 'molecular' remission and its significance in terms of relapse risk require further investigation.
14 Following the assumption that in such an aggressive pathology it is preferable to obtain CCRs with 'PCR negativity', we reviewed our series of 19 AML patients with inv(16) translocation to assess whether instances of PCR positivity could have been caused by differences in chemotherapy protocols or bone marrow transplantation (BMT) procedures.
In all cases, our PCR strategy, RNA isolation and RT-PCR procedure were performed as described. 5, 6 Experiments using inv(16) RNA in serial dilution of total RNA from normal individuals were also conducted: the level of sensitivity of type A fusion sequence amplification after nested PCR was of 1 tumor cell in 10 5 -10 6 non-neoplastic cells. At diagnosis, chimeric cDNAs were detected after amplification in 19 patients (Table 1) . Only one type out of nine reported chimeric transcripts was found, representing 1921 position fusion point within MYH11 spliced to position 495 of CBF␤ (type A). This finding is in line with the concept that AML with inv(16) is strictly associated with the type A transcript.
6,7 Three patients (Nos 1-3 in Table 1 ), who were only treated with non-ablative chemotherapy due to their age, died from AML: in these cases MRD was not evaluated. The remaining 16 patients (Nos 4-19) achieved CCR after different schedules of ablative induction and consolidation chemotherapy protocols ( Table 1) . Fifteen of these patients also achieved PCR negativity at the end of consolidation chemotherapy. The remaining patient (No. 4) relapsed with clonal evolution after 3 months from diagnosis and died of leukemia (no MRD assessment was possible). All 15 patients who achieved PCR negativity are currently alive in first (12 cases) or second (three cases) CCR (median overall survival 34 months; range 3-90 months) (Figure 1 ), confirming that AML with inv(16) is curable by ablative therapy in a high percentage of cases.
Of the 15 patients who achieved PCR negativity, 11 were further consolidated with BMT as follows: three received allogeneic BMT from an HLA-identical sibling, and eight underwent autologous BMT (ABMT).
17 Among the latter, three ABMTs (patient Nos 9, 10, 14) were performed with peripheral blood stem cells (PBSC) collected 18 at the end of consolidation, after G-CSF stimulation and five (patient Nos 5, 6, 12, 13, 18) with unpurged bone marrow stem cells. The other four patients were consolidated with one or two courses of chemotherapy alone (FLANG schedule) 19 and are pending ABMT procedures. Twelve patients have remained in first CCR with PCR negativity (median disease-free survival 26 months; range 1-51 months).
As regards the relationship between BMT procedure and
